Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Pegfilgrastim Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Pegfilgrastim Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Industry: Pharma & Healthcare

Published Date: 2025-02-21

Pages: 77 Pages

Report ld: 4131191

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Pegfilgrastim Biosimilar Market Size(US$)

CAGR 2025-2031

6.8%

Market Size,2031

USD 2,711

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 1,827 million

Market Forecast in 2031(Value)

US$ 2,711 million

CAGR

6.8%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Pegfilgrastim Biosimilar market size was US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The global Pegfilgrastim Biosimilar market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pegfilgrastim Biosimilar market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2020-2031.

MARKET SEGMENTATION

By Company

Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy’s Laboratories

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Chemotherapy Treatment
Transplantation

Segment by Application

Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales and revenue of Pegfilgrastim Biosimilar in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region.

Chapter 3: Detailed analysis of Pegfilgrastim Biosimilar manufacturers competitive landscape, sales, revenue, price, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Region analysis by company, by customer, by Type, by Application, sales, revenue, and price for each segment,

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pegfilgrastim Biosimilar revenue, gross margin, and recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Sales channels analysis

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Pegfilgrastim Biosimilar Product Scope

1.2 Pegfilgrastim Biosimilar by Type

1.2.1 Global Pegfilgrastim Biosimilar Sales by Type (2020 & 2024 & 2031)

1.2.2 Chemotherapy Treatment

1.2.3 Transplantation

1.3 Pegfilgrastim Biosimilar by Application

1.3.1 Global Pegfilgrastim Biosimilar Sales Comparison by Application (2020 & 2024 & 2031)

1.3.2 Hospital Pharmacies

1.3.3 Mail-Order Pharmacies

1.3.4 Retail Pharmacies

1.4 Global Pegfilgrastim Biosimilar Market Estimates and Forecasts (2020-2031)

1.4.1 Global Pegfilgrastim Biosimilar Market Size in Value Growth Rate (2020-2031)

1.4.2 Global Pegfilgrastim Biosimilar Market Size in Volume Growth Rate (2020-2031)

1.4.3 Global Pegfilgrastim Biosimilar Price Trends (2020-2031)

1.5 Assumptions and Limitations

2 Market Size and Prospective by Region

2.1 Global Pegfilgrastim Biosimilar Market Size by Region: 2020 VS 2024 VS 2031

2.2 Global Pegfilgrastim Biosimilar Retrospective Market Scenario by Region (2020-2025)

2.2.1 Global Pegfilgrastim Biosimilar Sales Market Share by Region (2020-2025)

2.2.2 Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2020-2025)

2.3 Global Pegfilgrastim Biosimilar Market Estimates and Forecasts by Region (2026-2031)

2.3.1 Global Pegfilgrastim Biosimilar Sales Estimates and Forecasts by Region (2026-2031)

2.3.2 Global Pegfilgrastim Biosimilar Revenue Forecast by Region (2026-2031)

2.4 Major Region and Emerging Market Analysis

2.4.1 North America Pegfilgrastim Biosimilar Market Size and Prospective (2020-2031)

2.4.2 Europe Pegfilgrastim Biosimilar Market Size and Prospective (2020-2031)

2.4.3 China Pegfilgrastim Biosimilar Market Size and Prospective (2020-2031)

2.4.4 Japan Pegfilgrastim Biosimilar Market Size and Prospective (2020-2031)

3 Global Market Size by Type

3.1 Global Pegfilgrastim Biosimilar Historic Market Review by Type (2020-2025)

3.1.1 Global Pegfilgrastim Biosimilar Sales by Type (2020-2025)

3.1.2 Global Pegfilgrastim Biosimilar Revenue by Type (2020-2025)

3.1.3 Global Pegfilgrastim Biosimilar Price by Type (2020-2025)

3.2 Global Pegfilgrastim Biosimilar Market Estimates and Forecasts by Type (2026-2031)

3.2.1 Global Pegfilgrastim Biosimilar Sales Forecast by Type (2026-2031)

3.2.2 Global Pegfilgrastim Biosimilar Revenue Forecast by Type (2026-2031)

3.2.3 Global Pegfilgrastim Biosimilar Price Forecast by Type (2026-2031)

3.3 Different Types Pegfilgrastim Biosimilar Representative Players

4 Global Market Size by Application

4.1 Global Pegfilgrastim Biosimilar Historic Market Review by Application (2020-2025)

4.1.1 Global Pegfilgrastim Biosimilar Sales by Application (2020-2025)

4.1.2 Global Pegfilgrastim Biosimilar Revenue by Application (2020-2025)

4.1.3 Global Pegfilgrastim Biosimilar Price by Application (2020-2025)

4.2 Global Pegfilgrastim Biosimilar Market Estimates and Forecasts by Application (2026-2031)

4.2.1 Global Pegfilgrastim Biosimilar Sales Forecast by Application (2026-2031)

4.2.2 Global Pegfilgrastim Biosimilar Revenue Forecast by Application (2026-2031)

4.2.3 Global Pegfilgrastim Biosimilar Price Forecast by Application (2026-2031)

4.3 New Sources of Growth in Pegfilgrastim Biosimilar Application

5 Competition Landscape by Players

5.1 Global Pegfilgrastim Biosimilar Sales by Players (2020-2025)

5.2 Global Top Pegfilgrastim Biosimilar Players by Revenue (2020-2025)

5.3 Global Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pegfilgrastim Biosimilar as of 2024)

5.4 Global Pegfilgrastim Biosimilar Average Price by Company (2020-2025)

5.5 Global Key Manufacturers of Pegfilgrastim Biosimilar, Manufacturing Sites & Headquarters

5.6 Global Key Manufacturers of Pegfilgrastim Biosimilar, Product Type & Application

5.7 Global Key Manufacturers of Pegfilgrastim Biosimilar, Date of Enter into This Industry

5.8 Manufacturers Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Pegfilgrastim Biosimilar Sales by Company

6.1.1.1 North America Pegfilgrastim Biosimilar Sales by Company (2020-2025)

6.1.1.2 North America Pegfilgrastim Biosimilar Revenue by Company (2020-2025)

6.1.2 North America Pegfilgrastim Biosimilar Sales Breakdown by Type (2020-2025)

6.1.3 North America Pegfilgrastim Biosimilar Sales Breakdown by Application (2020-2025)

6.1.4 North America Pegfilgrastim Biosimilar Major Customer

6.1.5 North America Market Trend and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe Pegfilgrastim Biosimilar Sales by Company

6.2.1.1 Europe Pegfilgrastim Biosimilar Sales by Company (2020-2025)

6.2.1.2 Europe Pegfilgrastim Biosimilar Revenue by Company (2020-2025)

6.2.2 Europe Pegfilgrastim Biosimilar Sales Breakdown by Type (2020-2025)

6.2.3 Europe Pegfilgrastim Biosimilar Sales Breakdown by Application (2020-2025)

6.2.4 Europe Pegfilgrastim Biosimilar Major Customer

6.2.5 Europe Market Trend and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China Pegfilgrastim Biosimilar Sales by Company

6.3.1.1 China Pegfilgrastim Biosimilar Sales by Company (2020-2025)

6.3.1.2 China Pegfilgrastim Biosimilar Revenue by Company (2020-2025)

6.3.2 China Pegfilgrastim Biosimilar Sales Breakdown by Type (2020-2025)

6.3.3 China Pegfilgrastim Biosimilar Sales Breakdown by Application (2020-2025)

6.3.4 China Pegfilgrastim Biosimilar Major Customer

6.3.5 China Market Trend and Opportunities

6.4 Japan Market: Players, Segments, Downstream and Major Customers

6.4.1 Japan Pegfilgrastim Biosimilar Sales by Company

6.4.1.1 Japan Pegfilgrastim Biosimilar Sales by Company (2020-2025)

6.4.1.2 Japan Pegfilgrastim Biosimilar Revenue by Company (2020-2025)

6.4.2 Japan Pegfilgrastim Biosimilar Sales Breakdown by Type (2020-2025)

6.4.3 Japan Pegfilgrastim Biosimilar Sales Breakdown by Application (2020-2025)

6.4.4 Japan Pegfilgrastim Biosimilar Major Customer

6.4.5 Japan Market Trend and Opportunities

7 Company Profiles and Key Figures

7.1 Novartis

7.1.1 Novartis Company Information

7.1.2 Novartis Business Overview

7.1.3 Novartis Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2020-2025)

7.1.4 Novartis Pegfilgrastim Biosimilar Products Offered

7.1.5 Novartis Recent Development

7.2 Mylan

7.2.1 Mylan Company Information

7.2.2 Mylan Business Overview

7.2.3 Mylan Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2020-2025)

7.2.4 Mylan Pegfilgrastim Biosimilar Products Offered

7.2.5 Mylan Recent Development

7.3 Coherus BioSciences

7.3.1 Coherus BioSciences Company Information

7.3.2 Coherus BioSciences Business Overview

7.3.3 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2020-2025)

7.3.4 Coherus BioSciences Pegfilgrastim Biosimilar Products Offered

7.3.5 Coherus BioSciences Recent Development

7.4 Mundipharma International

7.4.1 Mundipharma International Company Information

7.4.2 Mundipharma International Business Overview

7.4.3 Mundipharma International Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2020-2025)

7.4.4 Mundipharma International Pegfilgrastim Biosimilar Products Offered

7.4.5 Mundipharma International Recent Development

7.5 Biocon

7.5.1 Biocon Company Information

7.5.2 Biocon Business Overview

7.5.3 Biocon Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2020-2025)

7.5.4 Biocon Pegfilgrastim Biosimilar Products Offered

7.5.5 Biocon Recent Development

7.6 Intas Pharmaceuticals

7.6.1 Intas Pharmaceuticals Company Information

7.6.2 Intas Pharmaceuticals Business Overview

7.6.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2020-2025)

7.6.4 Intas Pharmaceuticals Pegfilgrastim Biosimilar Products Offered

7.6.5 Intas Pharmaceuticals Recent Development

7.7 Pfizer

7.7.1 Pfizer Company Information

7.7.2 Pfizer Business Overview

7.7.3 Pfizer Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2020-2025)

7.7.4 Pfizer Pegfilgrastim Biosimilar Products Offered

7.7.5 Pfizer Recent Development

7.8 Dr Reddy’s Laboratories

7.8.1 Dr Reddy’s Laboratories Company Information

7.8.2 Dr Reddy’s Laboratories Business Overview

7.8.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2020-2025)

7.8.4 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Products Offered

7.8.5 Dr Reddy’s Laboratories Recent Development

8 Pegfilgrastim Biosimilar Manufacturing Cost Analysis

8.1 Pegfilgrastim Biosimilar Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Key Suppliers of Raw Materials

8.2 Proportion of Manufacturing Cost Structure

8.3 Manufacturing Process Analysis of Pegfilgrastim Biosimilar

8.4 Pegfilgrastim Biosimilar Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

9.1 Marketing Channel

9.2 Pegfilgrastim Biosimilar Distributors List

9.3 Pegfilgrastim Biosimilar Customers

10 Pegfilgrastim Biosimilar Market Dynamics

10.1 Pegfilgrastim Biosimilar Industry Trends

10.2 Pegfilgrastim Biosimilar Market Drivers

10.3 Pegfilgrastim Biosimilar Market Challenges

10.4 Pegfilgrastim Biosimilar Market Restraints

11 Research Findings and Conclusion

12 Appendix

12.1 Research Methodology

12.1.1 Methodology/Research Approach

12.1.1.1 Research Programs/Design

12.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

12.1.2 Data Source

12.1.2.1 Secondary Sources

12.1.2.2 Primary Sources

12.2 Author Details

12.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Pegfilgrastim Biosimilar Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)

Table 2. Global Pegfilgrastim Biosimilar Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)

Table 3. Global Market Pegfilgrastim Biosimilar Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Pegfilgrastim Biosimilar Sales (K Units) by Region (2020-2025)

Table 5. Global Pegfilgrastim Biosimilar Sales Market Share by Region (2020-2025)

Table 6. Global Pegfilgrastim Biosimilar Revenue (US$ Million) Market Share by Region (2020-2025)

Table 7. Global Pegfilgrastim Biosimilar Revenue Share by Region (2020-2025)

Table 8. Global Pegfilgrastim Biosimilar Sales (K Units) Forecast by Region (2026-2031)

Table 9. Global Pegfilgrastim Biosimilar Sales Market Share Forecast by Region (2026-2031)

Table 10. Global Pegfilgrastim Biosimilar Revenue (US$ Million) Forecast by Region (2026-2031)

Table 11. Global Pegfilgrastim Biosimilar Revenue Share Forecast by Region (2026-2031)

Table 12. Global Pegfilgrastim Biosimilar Sales by Type (K Units) & (2020-2025)

Table 13. Global Pegfilgrastim Biosimilar Sales Share by Type (2020-2025)

Table 14. Global Pegfilgrastim Biosimilar Revenue by Type (US$ Million) & (2020-2025)

Table 15. Global Pegfilgrastim Biosimilar Price by Type (US$/Unit) & (2020-2025)

Table 16. Global Pegfilgrastim Biosimilar Sales by Type (K Units) & (2026-2031)

Table 17. Global Pegfilgrastim Biosimilar Revenue by Type (US$ Million) & (2026-2031)

Table 18. Global Pegfilgrastim Biosimilar Price by Type (US$/Unit) & (2026-2031)

Table 19. Representative Players of Each Type

Table 20. Global Pegfilgrastim Biosimilar Sales by Application (K Units) & (2020-2025)

Table 21. Global Pegfilgrastim Biosimilar Sales Share by Application (2020-2025)

Table 22. Global Pegfilgrastim Biosimilar Revenue by Application (US$ Million) & (2020-2025)

Table 23. Global Pegfilgrastim Biosimilar Price by Application (US$/Unit) & (2020-2025)

Table 24. Global Pegfilgrastim Biosimilar Sales by Application (K Units) & (2026-2031)

Table 25. Global Pegfilgrastim Biosimilar Revenue Market Share by Application (US$ Million) & (2026-2031)

Table 26. Global Pegfilgrastim Biosimilar Price by Application (US$/Unit) & (2026-2031)

Table 27. New Sources of Growth in Pegfilgrastim Biosimilar Application

Table 28. Global Pegfilgrastim Biosimilar Sales by Company (K Units) & (2020-2025)

Table 29. Global Pegfilgrastim Biosimilar Sales Share by Company (2020-2025)

Table 30. Global Pegfilgrastim Biosimilar Revenue by Company (US$ Million) & (2020-2025)

Table 31. Global Pegfilgrastim Biosimilar Revenue Share by Company (2020-2025)

Table 32. Global Pegfilgrastim Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pegfilgrastim Biosimilar as of 2024)

Table 33. Global Market Pegfilgrastim Biosimilar Average Price by Company (US$/Unit) & (2020-2025)

Table 34. Global Key Manufacturers of Pegfilgrastim Biosimilar, Manufacturing Sites & Headquarters

Table 35. Global Key Manufacturers of Pegfilgrastim Biosimilar, Product Type & Application

Table 36. Global Key Manufacturers of Pegfilgrastim Biosimilar, Date of Enter into This Industry

Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 38. North America Pegfilgrastim Biosimilar Sales by Company (2020-2025) & (K Units)

Table 39. North America Pegfilgrastim Biosimilar Sales Market Share by Company (2020-2025)

Table 40. North America Pegfilgrastim Biosimilar Revenue by Company (2020-2025) & (US$ Million)

Table 41. North America Pegfilgrastim Biosimilar Revenue Market Share by Company (2020-2025)

Table 42. North America Pegfilgrastim Biosimilar Sales by Type (2020-2025) & (K Units)

Table 43. North America Pegfilgrastim Biosimilar Sales Market Share by Type (2020-2025)

Table 44. North America Pegfilgrastim Biosimilar Sales by Application (2020-2025) & (K Units)

Table 45. North America Pegfilgrastim Biosimilar Sales Market Share by Application (2020-2025)

Table 46. Europe Pegfilgrastim Biosimilar Sales by Company (2020-2025) & (K Units)

Table 47. Europe Pegfilgrastim Biosimilar Sales Market Share by Company (2020-2025)

Table 48. Europe Pegfilgrastim Biosimilar Revenue by Company (2020-2025) & (US$ Million)

Table 49. Europe Pegfilgrastim Biosimilar Revenue Market Share by Company (2020-2025)

Table 50. Europe Pegfilgrastim Biosimilar Sales by Type (2020-2025) & (K Units)

Table 51. Europe Pegfilgrastim Biosimilar Sales Market Share by Type (2020-2025)

Table 52. Europe Pegfilgrastim Biosimilar Sales by Application (2020-2025) & (K Units)

Table 53. Europe Pegfilgrastim Biosimilar Sales Market Share by Application (2020-2025)

Table 54. China Pegfilgrastim Biosimilar Sales by Company (2020-2025) & (K Units)

Table 55. China Pegfilgrastim Biosimilar Sales Market Share by Company (2020-2025)

Table 56. China Pegfilgrastim Biosimilar Revenue by Company (2020-2025) & (US$ Million)

Table 57. China Pegfilgrastim Biosimilar Revenue Market Share by Company (2020-2025)

Table 58. China Pegfilgrastim Biosimilar Sales by Type (2020-2025) & (K Units)

Table 59. China Pegfilgrastim Biosimilar Sales Market Share by Type (2020-2025)

Table 60. China Pegfilgrastim Biosimilar Sales by Application (2020-2025) & (K Units)

Table 61. China Pegfilgrastim Biosimilar Sales Market Share by Application (2020-2025)

Table 62. Japan Pegfilgrastim Biosimilar Sales by Company (2020-2025) & (K Units)

Table 63. Japan Pegfilgrastim Biosimilar Sales Market Share by Company (2020-2025)

Table 64. Japan Pegfilgrastim Biosimilar Revenue by Company (2020-2025) & (US$ Million)

Table 65. Japan Pegfilgrastim Biosimilar Revenue Market Share by Company (2020-2025)

Table 66. Japan Pegfilgrastim Biosimilar Sales by Type (2020-2025) & (K Units)

Table 67. Japan Pegfilgrastim Biosimilar Sales Market Share by Type (2020-2025)

Table 68. Japan Pegfilgrastim Biosimilar Sales by Application (2020-2025) & (K Units)

Table 69. Japan Pegfilgrastim Biosimilar Sales Market Share by Application (2020-2025)

Table 70. Novartis Company Information

Table 71. Novartis Description and Business Overview

Table 72. Novartis Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Novartis Pegfilgrastim Biosimilar Product

Table 74. Novartis Recent Development

Table 75. Mylan Company Information

Table 76. Mylan Description and Business Overview

Table 77. Mylan Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Mylan Pegfilgrastim Biosimilar Product

Table 79. Mylan Recent Development

Table 80. Coherus BioSciences Company Information

Table 81. Coherus BioSciences Description and Business Overview

Table 82. Coherus BioSciences Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Coherus BioSciences Pegfilgrastim Biosimilar Product

Table 84. Coherus BioSciences Recent Development

Table 85. Mundipharma International Company Information

Table 86. Mundipharma International Description and Business Overview

Table 87. Mundipharma International Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Mundipharma International Pegfilgrastim Biosimilar Product

Table 89. Mundipharma International Recent Development

Table 90. Biocon Company Information

Table 91. Biocon Description and Business Overview

Table 92. Biocon Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Biocon Pegfilgrastim Biosimilar Product

Table 94. Biocon Recent Development

Table 95. Intas Pharmaceuticals Company Information

Table 96. Intas Pharmaceuticals Description and Business Overview

Table 97. Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Intas Pharmaceuticals Pegfilgrastim Biosimilar Product

Table 99. Intas Pharmaceuticals Recent Development

Table 100. Pfizer Company Information

Table 101. Pfizer Description and Business Overview

Table 102. Pfizer Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Pfizer Pegfilgrastim Biosimilar Product

Table 104. Pfizer Recent Development

Table 105. Dr Reddy’s Laboratories Company Information

Table 106. Dr Reddy’s Laboratories Description and Business Overview

Table 107. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product

Table 109. Dr Reddy’s Laboratories Recent Development

Table 110. Production Base and Market Concentration Rate of Raw Material

Table 111. Key Suppliers of Raw Materials

Table 112. Pegfilgrastim Biosimilar Distributors List

Table 113. Pegfilgrastim Biosimilar Customers List

Table 114. Pegfilgrastim Biosimilar Market Trends

Table 115. Pegfilgrastim Biosimilar Market Drivers

Table 116. Pegfilgrastim Biosimilar Market Challenges

Table 117. Pegfilgrastim Biosimilar Market Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

List of Figures

Figure 1. Pegfilgrastim Biosimilar Product Picture

Figure 2. Global Pegfilgrastim Biosimilar Sales (US$ Million) by Type (2020 & 2024 & 2031)

Figure 3. Global Pegfilgrastim Biosimilar Sales Market Share by Type in 2024 & 2031

Figure 4. Chemotherapy Treatment Product Picture

Figure 5. Transplantation Product Picture

Figure 6. Global Pegfilgrastim Biosimilar Sales (US$ Million) by Application (2020 & 2024 & 2031)

Figure 7. Global Pegfilgrastim Biosimilar Sales Market Share by Application in 2024 & 2031

Figure 8. Hospital Pharmacies Examples

Figure 9. Mail-Order Pharmacies Examples

Figure 10. Retail Pharmacies Examples

Figure 11. Global Pegfilgrastim Biosimilar Sales, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Pegfilgrastim Biosimilar Sales Growth Rate (2020-2031) & (US$ Million)

Figure 13. Global Pegfilgrastim Biosimilar Sales (K Units) Growth Rate (2020-2031)

Figure 14. Global Pegfilgrastim Biosimilar Price Trends Growth Rate (2020-2031) & (US$/Unit)

Figure 15. Pegfilgrastim Biosimilar Report Years Considered

Figure 16. Global Market Pegfilgrastim Biosimilar Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Figure 17. Global Pegfilgrastim Biosimilar Revenue Market Share by Region: 2020 VS 2024

Figure 18. North America Pegfilgrastim Biosimilar Revenue (US$ Million) Growth Rate (2020-2031)

Figure 19. North America Pegfilgrastim Biosimilar Sales (K Units) Growth Rate (2020-2031)

Figure 20. Europe Pegfilgrastim Biosimilar Revenue (US$ Million) Growth Rate (2020-2031)

Figure 21. Europe Pegfilgrastim Biosimilar Sales (K Units) Growth Rate (2020-2031)

Figure 22. China Pegfilgrastim Biosimilar Revenue (US$ Million) Growth Rate (2020-2031)

Figure 23. China Pegfilgrastim Biosimilar Sales (K Units) Growth Rate (2020-2031)

Figure 24. Japan Pegfilgrastim Biosimilar Revenue (US$ Million) Growth Rate (2020-2031)

Figure 25. Japan Pegfilgrastim Biosimilar Sales (K Units) Growth Rate (2020-2031)

Figure 26. Global Pegfilgrastim Biosimilar Revenue Share by Type (2020-2025)

Figure 27. Global Pegfilgrastim Biosimilar Sales Share by Type (2026-2031)

Figure 28. Global Pegfilgrastim Biosimilar Revenue Share by Type (2026-2031)

Figure 29. Global Pegfilgrastim Biosimilar Revenue Share by Application (2020-2025)

Figure 30. Global Pegfilgrastim Biosimilar Revenue Growth Rate by Application in 2020 & 2024

Figure 31. Global Pegfilgrastim Biosimilar Sales Share by Application (2026-2031)

Figure 32. Global Pegfilgrastim Biosimilar Revenue Share by Application (2026-2031)

Figure 33. Global Pegfilgrastim Biosimilar Sales Share by Company (2024)

Figure 34. Global Pegfilgrastim Biosimilar Revenue Share by Company (2024)

Figure 35. Global 5 Largest Pegfilgrastim Biosimilar Players Market Share by Revenue in Pegfilgrastim Biosimilar: 2020 & 2024

Figure 36. Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 37. Manufacturing Cost Structure of Pegfilgrastim Biosimilar

Figure 38. Manufacturing Process Analysis of Pegfilgrastim Biosimilar

Figure 39. Pegfilgrastim Biosimilar Industrial Chain

Figure 40. Channels of Distribution (Direct Vs Distribution)

Figure 41. Distributors Profiles

Figure 42. Bottom-up and Top-down Approaches for This Report

Figure 43. Data Triangulation

Figure 44. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 6.8% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

What is the annual compound growth rate of the global Pegfilgrastim Biosimilar market size from 2025 to 2031? shouQi

What was the global market size of Pegfilgrastim Biosimilar in 2031? shouQi

Which companies rank high in the global Pegfilgrastim Biosimilar market? shouQi

What was the global market size of Pegfilgrastim Biosimilar in 2025? shouQi

Related Reports

Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1827 million in 2025 and is projected to reach US$ 2877 million, growing at a CAGR of 6.8% from 2026 to 2032.
Published Date: 2026-07-09
Pages: 135
USD 3950.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2026
The global Pegfilgrastim Biosimilar market was valued at US$ 1827 million in 2025 and is anticipated to reach US$ 2877 million by 2032, at a CAGR of 6.8% from 2026 to 2032.
Published Date: 2026-04-21
Pages: 108
USD 2900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1721 million in 2024 to US$ 2711 million by 2031, at a CAGR of 6.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-25
Pages: 149
USD 4900.00
(Single User License)
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 106
USD 3950.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2025
The global market for Pegfilgrastim Biosimilar was valued at US$ 1721 million in the year 2024 and is projected to reach a revised size of US$ 2711 million by 2031, growing at a CAGR of 6.8% during the forecast period.
Published Date: 2025-02-21
Pages: 82
USD 2900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Insights, Forecast to 2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-04-25
Pages: 91
USD 4900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-02-07
Pages: 82
USD 2900.00
(Single User License)
Pegfilgrastim Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-01-11
Pages: 101
USD 3950.00
(Single User License)

Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1827 million in 2025 and is projected to reach US$ 2877 million, growing at a CAGR of 6.8% from 2026 to 2032.
Published: 2026-07-09
Pages: 135
USD 3950.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2026
The global Pegfilgrastim Biosimilar market was valued at US$ 1827 million in 2025 and is anticipated to reach US$ 2877 million by 2032, at a CAGR of 6.8% from 2026 to 2032.
Published: 2026-04-21
Pages: 108
USD 2900.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1721 million in 2024 to US$ 2711 million by 2031, at a CAGR of 6.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-25
Pages: 149
USD 4900.00 (Single User License)
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 106
USD 3950.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2025
The global market for Pegfilgrastim Biosimilar was valued at US$ 1721 million in the year 2024 and is projected to reach a revised size of US$ 2711 million by 2031, growing at a CAGR of 6.8% during the forecast period.
Published: 2025-02-21
Pages: 82
USD 2900.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Insights, Forecast to 2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-04-25
Pages: 91
USD 4900.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-02-07
Pages: 82
USD 2900.00 (Single User License)
Pegfilgrastim Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-01-11
Pages: 101
USD 3950.00 (Single User License)